BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-0635-2024

Hikma Pharmaceuticals USA Inc. · Cherry Hill, NJ

Class I — life-threatening Ongoing 675 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

Acetaminophen Injection, 1,000 mg per 100 mL (10 mg/mL), 100 mL Single Dose bags, For Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica (Portugal), SA, distributed by Hikma Pharmaceuticals USA Inc Berkeley Heights, NJ NDC 0143-9386-01

Lot / code: Lot #24070381; Exp. 09/30/2025

Quantity: 31,400 bags

Reason for recall

Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL)

Recall record

Recall number
D-0635-2024
Classification
Class I
Status
Ongoing
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Letter
Distribution
OH and PR
Recall initiated
2024-07-08
Classified by FDA Center
2024-08-16
FDA published
2024-08-28
Recalling firm
Hikma Pharmaceuticals USA Inc.
Firm location
Cherry Hill, NJ

Drug identification

Brand name(s)
ACETAMINOPHEN
Generic name(s)
ACETAMINOPHEN
Manufacturer(s)
Hikma Pharmaceuticals USA Inc.
NDC(s)
0143-9386
Route(s)
INTRAVENOUS

Operational response

A Class I recall indicates a strong likelihood of serious adverse health consequence or death. Pull affected lots from active dispensing immediately. Segregate inventory in a marked, locked location pending destruction or return. If product has already been dispensed, identify affected patients and contact them by your standard recall-notification protocol.

For the official FDA enforcement record, see FDA's Recall Search.

‹ All recalls